The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles

Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax

(2020) Yu-Wen Wang et al.   ANNALS OF HEMATOLOGY

Very late acute myeloid leukemia relapse: clinical features, treatment and outcome

(2020) Sabrina Mariani et al.   LEUKEMIA & LYMPHOMA

Chapter 22: Structural and signaling functions of integrins

(2020) Yasmin A. Kadry et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

The Evolving AML Genomic Landscape: Therapeutic Implications

(2020) Sachi Horibata et al.   CURRENT CANCER DRUG TARGETS

New perspectives on integrin-dependent adhesions

(2020) Magdalene Michael et al.   CURRENT OPINION IN CELL BIOLOGY

Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia

(2020) Elise Aasebø et al.   Cancers

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

(2019) Musa Yilmaz et al.   Blood Cancer Journal

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

(2019) Sibylle Cocciardi et al.   Nature Communications

Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

(2019) Brian Ball et al.   HAEMATOLOGICA

Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach

(2019) Daniel J. Lee et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response

(2019) David Sharon et al.   Science Translational Medicine

Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia

(2019) Jeremy M. Schraw et al.   EBioMedicine

Consensus on MRD in AML?

(2018) Elisabeth Paietta   BLOOD

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Actin Remodeling in Regulated Exocytosis: Toward a Mesoscopic View

(2018) Pin Li et al.   TRENDS IN CELL BIOLOGY

Progress and predictions: AML in 2018

(2018) Jacob M. Rowe   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

The PRIDE database and related tools and resources in 2019: improving support for quantification data

(2018) Yasset Perez-Riverol et al.   NUCLEIC ACIDS RESEARCH

The constitutive protease release by primary human acute myeloid leukemia cells

(2017) Maria Honnemyr et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia

(2017) M. Ryan Corces et al.   Frontiers in Oncology

Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells

(2016) Shao Xie et al.   ACTA PHARMACOLOGICA SINICA

Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients

(2016) Maria Hernandez-Valladares et al.   BIOLOGICAL PROCEDURES ONLINE

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Molecular mechanisms regulating secretory organelles and endosomes in neutrophils and their implications for inflammation

(2016) Mahalakshmi Ramadass et al.   IMMUNOLOGICAL REVIEWS

The Perseus computational platform for comprehensive analysis of (prote)omics data

(2016) Stefka Tyanova et al.   NATURE METHODS

The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible

(2016) Damian Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition

(2016) Eric W. Deutsch et al.   NUCLEIC ACIDS RESEARCH

MRD in AML: does it already guide therapy decision-making?

(2016) G. Ossenkoppele et al.   Hematology-American Society of Hematology Education Program

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators

(2016) Annette K. Brenner et al.   Frontiers in Immunology

Avoiding abundance bias in the functional annotation of posttranslationally modified proteins

(2015) Christian Schölz et al.   NATURE METHODS

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2015) Nestor Ramos et al.   Journal of Clinical Medicine

Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells

(2014) Nils A Kulak et al.   NATURE METHODS

Acute myeloid leukaemia in adults

(2013) Felicetto Ferrara et al.   LANCET

Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells

(2013) P. Casado et al.   Science Signaling

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Detecting overlapping protein complexes in protein-protein interaction networks

(2012) Tamás Nepusz et al.   NATURE METHODS

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Therapeutic potential of mitochondrial translation inhibition for treatment of acute myeloid leukemia

(2012) Aaron D Schimmer et al.   Expert Review of Hematology

Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia

(2011) Marko Škrtić et al.   CANCER CELL

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release

(2010) Håkon Reikvam et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

IsobariQ: Software for Isobaric Quantitative Proteomics using IPTL, iTRAQ, and TMT

(2010) Magnus Ø. Arntzen et al.   JOURNAL OF PROTEOME RESEARCH

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation

(2009) Håkon Reikvam et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Improved visualization of protein consensus sequences by iceLogo

(2009) Niklaas Colaert et al.   NATURE METHODS

Universal sample preparation method for proteome analysis

(2009) Jacek R Wiśniewski et al.   NATURE METHODS

A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics

(2009) Jürgen Cox et al.   Nature Protocols

Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death

(2008) G. Gausdal et al.   BLOOD

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

(2008) M. A. Sekeres et al.   BLOOD

BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams

(2008) Tim Hulsen et al.   BMC GENOMICS

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

(2008) Jürgen Cox et al.   NATURE BIOTECHNOLOGY